CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting

By GlobeNewswire

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.

Presentation details are as follows:

Date & Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET)
Session Type: Poster
Session Title: MRI & Imaging

Poster Number: P077
Title: Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies
Presenter: Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular Imaging Research at Austin Health

Poster Number: P082
Title: Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer’s disease spectrum
Presenter: Gerard Nisal Bischof, PD, Director Medical Imaging at Lantheus

About Lantheus 
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.